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INTRODUCTION 
 
 Pancreatic cancer is the 4th most aggressive cancer in 
the western world with less than 34% of patients surviving 
past 5 years [1]. Lack of specific symptoms results in a 
delay in diagnosis. Theranostics are new platforms, which 
offer simultaneous diagnosis and therapy resulting in a 
decrease in treatment time [2]. Here treatments are 
conjugated onto diagnostics by stimuli responsive binding 
allowing for controlled drug release resulting in a rapid and 
localised clinical effect. Hybrid nanoparticles are composed 
of an iron oxide core surrounded by a rigid gold shell [3]. 
These particles undergo manipulation due to inherent 
magnetism of the core whilst laser irradiation of their gold 
shell results in localised heating due to surface plasmon 
resonance. Hence, they can be utilised as diagnostics using 
MRI and laser irradiation can be used as a trigger for drug 
release. 
 
MATERIALS AND METHODS 
 
 Proof of concept studies have been carried out using a 
novel bisnaphthalamido (BNIP) based drug series. BNIPs 
are a series of novel compounds, which have exhibited 
exciting potential as chemotherapy agents [4,5]. HNPs were 
fabricated and characterised using photon correlation 
spectroscopy (PCS), transmission electron microscopy 
(TEM), magnetic resonance imaging (MRI), super quantum 
interference device (SQUID) and zeta potential 
measurement. Drug conjugation and release was quantified 
using reverse phase high performance liquid 
chromatography (HPLC). Cellular response and cytotoxicity 
assays were carried out using trypan blue exclusion, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay and atomic force microscopy.  
  
RESULTS AND DISCUSSION 
 
In our studies, we designed hybrid nanoparticles (50 nm) 
capable of drug loading onto their surface (3:1:0.25, 
Drug:Fe:Au). By exploiting the gold surface-to-drug 
interaction of a range of novel Bisnaphtalamido based 
agents (Fig. 1) a system with heat triggered drug release was 
produced. In vitro studies of these formulations showed the 
novel formulations possess a 10-fold lower IC50 value when 
compared with the free drug after only 24 h. These 
cytotoxicity studies combined with cellular uptake studies 
showed the formulations to be significantly more effective 
compared with gemcitabine (a nucleoside analogue 
marketed as Gemzar). In vivo trials have commenced to 
further elucidate their viability for use as theranostics. 
 
 
 
 
 
 
 
 
Fig. 1. Drug compounds attached to HNPs 
 
CONCLUSIONS 
 
 These data highlight the potential of HNPs as dual 
imaging agents and contrast agents for pancreatic cancer 
therapy. 
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